PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study-Reference-Cited by-同舟云学术

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Published:2019-02 Issue:2 Volume:20 Page:202-215
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Casasnovas René-Olivier,Bouabdallah Reda,Brice Pauline,Lazarovici Julien,Ghesquieres Hervé,Stamatoullas Aspasia,Dupuis Jehan,Gac Anne-Claire,Gastinne Thomas,Joly Bertrand,Bouabdallah Krimo,Nicolas-Virelizier Emmanuelle,Feugier Pierre,Morschhauser Franck,Delarue Richard,Farhat Hassan,Quittet Philippe,Berriolo-Riedinger Alina,Tempescul Adrian,Edeline Véronique,Maisonneuve Hervé,Fornecker Luc-Matthieu,Lamy Thierry,Delmer Alain,Dartigues Peggy,Martin Laurent,André Marc,Mounier Nicolas,Traverse-Glehen Alexandra,Meignan Michel

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!;Diehl;J Clin Oncol,2003

2. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study;Engert;J Clin Oncol,2009

3. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial;Federico;J Clin Oncol,2009

4. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned;Viviani;N Engl J Med,2011

5. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial;Mounier;Ann Oncol,2014

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas;PET Clinics;2024-10

2. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

3. Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD;Frontiers in Oncology;2024-09-05

4. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

5. Should Adolescents and Young Adults With Hodgkin Lymphoma Be Treated as Children or Adults?;2024-08-28